What is the way forward for undruggable tumour targets?
2026 ESMO TAT Honorary Awardee, Prof. Timothy A. Yap, sees a bright future ahead for novel synthetic lethal strategies, driven by advances in technology and novel biomarkers
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Trustworthy and explainable AI – a key to equitable oncology?
Mitigating research biases by rigorous data analysis and validation can pave the way for a wider adoption of artificial intelligence in cancer care
RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients
Cancer Research
Rethinking the immunotherapy paradigm for a sustainable and equal cancer care
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access
Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
The power of dual-layer genomics in precision oncology
Integrating DNA and RNA profiling is a promising approach to advance cancer characterisation and guide clinical decision-making
Shaping the use of AI in oncology
ESMO plays a central role in developing long-lasting recommendations for a safe and effective use of artificial intelligence supporting oncology stakeholders
Artificial intelligence is expediting the development of therapeutic immunotherapies
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic